Buckwold V E, Xu Z, Yen T S, Ou J H
Department of Molecular Microbiology and Immunology, University of Southern California School of Medicine, Los Angeles 90033, USA.
J Gen Virol. 1997 Aug;78 ( Pt 8):2055-65. doi: 10.1099/0022-1317-78-8-2055.
The basal core promoter (BCP) of hepatitis B virus (HBV) directs the transcription of both precore RNA and core RNA which code for e antigen (HBeAg) and core antigen, respectively. A double mutation in the BCP which converts nucleotide (nt) 1762 from A to T and nt 1764 from G to A is frequently observed in patients with chronic hepatitis B. We recently demonstrated that this double mutation prevented the binding of a liver-enriched factor (LEF) to the BCP, suppressed only precore RNA transcription (and hence HBeAg expression), and enhanced progeny virus production. In order to understand the mechanism for the selection of this frequent double mutation, we have extended our previous studies to further characterize LEF and to compare the effects of this double-nucleotide mutation (M1) with each single-nucleotide mutation at nt 1762 (M2) and nt 1764 (M3). Our results indicate that LEF is likely composed of a heterodimer formed between the transcription factor chicken ovalbumin upstream promoter-transcription factor (COUP-TF) and an unidentified liver-enriched factor. Further studies reveal that both M1 and M2 prevent the binding of LEF to the BCP, suppress only precore RNA transcription, and increase the efficiency of progeny virus synthesis. In contrast, M3 retains some LEF binding activity, does not suppress HBV RNA transcription, and reduces slightly the efficiency of virus progeny synthesis. The reduced ability of M3 to replicate indicates that it has no selection advantage in itself at the level of the infected hepatocyte. In spite of its enhanced replication rate, M2 is rarely detected in HBV patients. This indicates the involvement of factors other than intracellular replication rates in the selection of these virus variants in the infected individual.
乙型肝炎病毒(HBV)的基础核心启动子(BCP)指导前核心RNA和核心RNA的转录,它们分别编码e抗原(HBeAg)和核心抗原。在慢性乙型肝炎患者中经常观察到BCP中的双突变,该突变将核苷酸(nt)1762由A转换为T,nt 1764由G转换为A。我们最近证明,这种双突变阻止了肝脏富集因子(LEF)与BCP的结合,仅抑制前核心RNA转录(从而抑制HBeAg表达),并提高子代病毒的产生。为了了解这种常见双突变的选择机制,我们扩展了先前的研究,以进一步表征LEF,并比较这种双核苷酸突变(M1)与nt 1762(M2)和nt 1764(M3)处的每个单核苷酸突变的影响。我们的结果表明,LEF可能由转录因子鸡卵清蛋白上游启动子转录因子(COUP-TF)和一个未鉴定的肝脏富集因子之间形成的异二聚体组成。进一步的研究表明,M1和M2都阻止LEF与BCP的结合,仅抑制前核心RNA转录,并提高子代病毒合成的效率。相比之下,M3保留了一些LEF结合活性,不抑制HBV RNA转录,并略微降低病毒子代合成的效率。M3复制能力的降低表明它在受感染肝细胞水平上本身没有选择优势。尽管M2的复制率有所提高,但在HBV患者中很少检测到。这表明在受感染个体中这些病毒变体的选择涉及细胞内复制率以外的因素。